Senior Medical Director, Gene-Editing Clinical Development

Editas Medicine; Cambridge (MA); On-site; USD 345,000 - 375,000; Full time

Benefits offered by this job

Health plan

Dental and Vision Insurance

401(k) plan with company match

Tuition Reimbursement

Job summary

Editas Medicine, based in Cambridge, MA, seeks a Senior Medical Director, Clinical Development to lead global programs targeting genetic diseases and gene-editing therapies. You will design and oversee early-phase trials, drive translational endpoints, and align regulatory strategies with program goals.

Ideal candidates hold an MD or MD/PhD with 10+ years in clinical R&D, proven leadership of cardiovascular or rare disease programs, and a track record in cross-functional collaboration and

Qualifications

• MD or MD/PhD with training in cardiovascular diseases, internal medicine, rare disease, or related fields.
• 10+ years of industry experience in clinical research and development, including leadership of early-stage cardiovascular disease and/or rare disease programs.
• Experience designing and executing global clinical trials; experience with gene-editing, gene therapy, or advanced modalities is a plus.
• Hands-on experience establishing or overseeing clinical trials, including collaboration with local CROs, investigators, and hospital partners.
• Willingness to travel to develop and oversee global clinical trials.
• Strong understanding of clinical trial methodology, translational science, safety monitoring, and global regulatory pathways.
• Proven ability to work effectively in matrixed teams and influence across scientific, operational, and business stakeholders.
• Excellent written and verbal communication skills, including presenting to investigators, regulators, and governance bodies.
• Strategic, pragmatic, and able to thrive in a high-growth biotech environment.
• Strong network of clinical investigators and scientific collaborators globally.

Responsibilities

• Lead the design, medical oversight, and operational execution of clinical development strategies for EDIT-401, with emphasis on early development (FIH, Phase 1-2) and translational endpoints relevant to gene editing.
• Serve as clinical program lead, providing day-to-day medical and scientific leadership to ensure high-quality clinical execution and data integrity.
• Partner with R&D to integrate biomarker strategy, safety monitoring approaches, and indication rationale.
• Contribute to the development and refinement of clinical development plans and study protocols, ensuring alignment with global regulatory expectations.
• Support preparation of clinical documents for regulatory submissions (IND, CTA, NDA/BLA components, study reports).
• Collaborate with regulatory affairs and region-specific experts for interactions with global regulatory agencies.
• Work closely with Clinical Operations, Regulatory, Project Management, CMC, Analytical Sciences, and Commercial for integrated planning.
• Partner with Research teams on indication selection, biomarker development, and advancing new pipeline programs.
• Provide clinical leadership in cross-functional forums, risk assessments, data reviews, and stage-gate processes.
• Cultivate networks with global investigators, KOLs, and patient advocacy groups.
• Lead or support scientific advisory boards, investigator meetings, and data-review interactions.
• Represent the company at scientific conferences and contribute to manuscripts, abstracts, and presentations.

Education

MD or MD/PhD with training in cardiovascular diseases, internal medicine, rare disease, or related fields

Job description

Editas Medicine, based in Cambridge, MA, seeks a Senior Medical Director, Clinical Development to lead global programs targeting genetic diseases and gene-editing therapies. You will design and oversee early-phase trials, drive translational endpoints, and align regulatory strategies with program goals.

Ideal candidates hold an MD or MD/PhD with 10+ years in clinical R&D, proven leadership of cardiovascular or rare disease programs, and a track record in cross-functional collaboration and